's () Michael Hunt chats to Proactive London's Andrew Scott following the release of its year-end update.
The cell therapy specialist has two clinical trials underway and is looking at partnerships or licensing deals for its three major programmes.
Hunt says with a partnership deal for its cell technology in China now secured they're pursuing other collaborations or out-licensing deals across all its programmes.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE